Nothing Special   »   [go: up one dir, main page]

MX2010009190A - Anticuerpos anti-c5ar humanizados. - Google Patents

Anticuerpos anti-c5ar humanizados.

Info

Publication number
MX2010009190A
MX2010009190A MX2010009190A MX2010009190A MX2010009190A MX 2010009190 A MX2010009190 A MX 2010009190A MX 2010009190 A MX2010009190 A MX 2010009190A MX 2010009190 A MX2010009190 A MX 2010009190A MX 2010009190 A MX2010009190 A MX 2010009190A
Authority
MX
Mexico
Prior art keywords
present
humanized antibodies
humanized anti
receptor
human
Prior art date
Application number
MX2010009190A
Other languages
English (en)
Inventor
Peter Whitfeld
David Zahra
Charles Mackay
Original Assignee
G2 Inflammation Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G2 Inflammation Pty Ltd filed Critical G2 Inflammation Pty Ltd
Publication of MX2010009190A publication Critical patent/MX2010009190A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se dirige a anticuerpos humanizados que se unen al receptor C5a humano y su uso como agentes terapéuticos y de diagnóstico. La presente invención, se dirige además hacia secuencias de ácido nucleico que codifican para los anticuerpos humanizados, y su expresión en células hospederas recombinantes. En particular, la presente invención se dirige hacia anticuerpos humanizados derivados del anticuerpo murino 7F3 que se une específicamente al receptor C5a humano.
MX2010009190A 2008-02-20 2009-02-19 Anticuerpos anti-c5ar humanizados. MX2010009190A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6653908P 2008-02-20 2008-02-20
PCT/AU2009/000184 WO2009103113A1 (en) 2008-02-20 2009-02-19 HUMANIZED ANTI-C5aR ANTIBODIES

Publications (1)

Publication Number Publication Date
MX2010009190A true MX2010009190A (es) 2010-09-10

Family

ID=40984994

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009190A MX2010009190A (es) 2008-02-20 2009-02-19 Anticuerpos anti-c5ar humanizados.

Country Status (14)

Country Link
US (3) US8268972B2 (es)
EP (2) EP2826791A3 (es)
JP (2) JP2011515073A (es)
KR (1) KR20100117120A (es)
CN (2) CN101970494B (es)
AU (1) AU2009217224B2 (es)
BR (1) BRPI0907532A2 (es)
CA (1) CA2714296A1 (es)
ES (1) ES2562627T3 (es)
IL (1) IL207217A (es)
MX (1) MX2010009190A (es)
RU (1) RU2010138612A (es)
WO (1) WO2009103113A1 (es)
ZA (1) ZA201005348B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003202297C1 (en) 2002-01-25 2006-05-18 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
CN101506237B (zh) * 2006-08-22 2014-05-07 G2炎症私人有限公司 具有改进性能的抗-C5aR抗体
EP2826791A3 (en) * 2008-02-20 2015-07-29 Novo Nordisk A/S Humanized anti-C5aR antibodies
JP2011526591A (ja) 2008-06-30 2011-10-13 ノボ・ノルデイスク・エー／エス 抗ヒトインターロイキン−２０抗体
CN102164965B (zh) * 2008-09-26 2016-03-30 Ucb医药有限公司 生物产品
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
EP2538973A2 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Stable antibody containing compositions
ES2642512T3 (es) 2010-03-01 2017-11-16 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
CA2800188A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
EP2468295A1 (en) 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
PT3424953T (pt) 2011-06-06 2020-11-03 Novo Nordisk As Anticorpos terapêuticos
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
GB201220242D0 (en) * 2012-11-09 2012-12-26 Fusion Antibodies Ltd Antibody
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
DK2994488T3 (da) * 2013-05-08 2022-10-03 Novo Nordisk As Anvendelse af c5ar-antagonister
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SG11201608696RA (en) * 2014-05-05 2016-11-29 Regeneron Pharma Humanized c5 and c3 animals
WO2016081490A1 (en) 2014-11-17 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
EP3633371A1 (en) * 2014-12-18 2020-04-08 F. Hoffmann-La Roche AG Assay and method for determining cdc eliciting antibodies
ES2846748T3 (es) 2015-03-30 2021-07-29 Regeneron Pharma Regiones constantes de cadenas pesadas con unión reducida a receptores Fc gamma
WO2016179285A1 (en) 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
BR112019019595A2 (pt) * 2017-03-23 2020-04-14 Univ Pennsylvania anticorpo, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema complemento de um indivíduo, e, célula
WO2019014586A1 (en) * 2017-07-14 2019-01-17 Cytomx Therapeutics, Inc. ANTI-CD166 ANTIBODIES AND USES THEREOF
JP6511200B1 (ja) * 2017-12-14 2019-05-15 硬化クローム工業株式会社 冷却ロール、およびそれを用いた熱可塑性樹脂シートの製造方法
KR20210018906A (ko) * 2018-06-07 2021-02-18 케모센트릭스, 인크. Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과
KR20210054528A (ko) 2018-08-31 2021-05-13 리제너론 파아마슈티컬스, 인크. Cd3/c20 이중특이적 항체에 대한 사이토카인 방출 증후군을 경감시키는 투약 전략
CN109439662B (zh) * 2018-11-15 2020-09-01 北京大学第三医院 用于C5aR1基因敲除的sgRNA、载体以及构建方法和检测方法
TW202140553A (zh) * 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
MX2023008302A (es) * 2021-01-13 2023-09-25 Visterra Inc Anticuerpos humanizados contra el receptor 1 del componente 5a del complemento y métodos de uso de estos.
WO2024193714A1 (zh) * 2023-03-23 2024-09-26 科济生物医药（上海）有限公司 细胞免疫疗法的组合物和方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JPH02262599A (ja) 1989-01-03 1990-10-25 Merck & Co Inc ヒト多形核白血球からの精製Ｃ５ａレセプター
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5284746A (en) 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
EP0672068A4 (en) 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5480974A (en) * 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5861272A (en) 1995-06-02 1999-01-19 Human Genome Sciences, Inc. C5A receptor
JPH08109200A (ja) 1994-08-19 1996-04-30 Takeda Chem Ind Ltd 抗Ｃ５ａレセプター抗体、その製造法および用途
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP0832231A2 (en) 1995-06-05 1998-04-01 Incyte Pharmaceuticals, Inc. A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR
PT1500329E (pt) 1996-12-03 2012-06-18 Amgen Fremont Inc Anticorpos humanos que se ligam especificamente ao tnf alfa humano
CA2279344A1 (en) 1997-01-31 1998-08-06 Incyte Pharmaceuticals, Inc. Human c5a-like receptor
JP4187277B2 (ja) 1997-04-30 2008-11-26 エンゾン ファーマシューティカルズ， インコーポレイテッド グリコシル化し得る抗原結合単鎖タンパク質、それらの生成および使用
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
AU2002231194A1 (en) 2000-11-07 2002-05-21 Genetics Institute, Llc G protein-coupled receptor protein and nucleic acid molecules and uses therefor
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
AU2002246733B2 (en) 2000-12-19 2007-09-20 Altor Bioscience Corporation Transgenic animals comprising a humanized immune system
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
JP4603261B2 (ja) 2001-09-27 2010-12-22 メルク・シャープ・エンド・ドーム・コーポレイション ヒト化カルシトニン遺伝子関連ペプチド受容体をコードする単離ｄｎａ分子、関連する非ヒトトランスジェニック動物及びアッセイ方法
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
AU2003202297C1 (en) * 2002-01-25 2006-05-18 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
JP2006513702A (ja) 2002-09-09 2006-04-27 ヌラ インコーポレーティッド Ｇタンパク質共役受容体およびその使用
DE60333228D1 (de) 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
US8071839B2 (en) 2003-12-24 2011-12-06 G2 Inflammation Pty Ltd Transgenic mouse comprising a polynucleotide encoding human or humanized C5aR and methods of production and use
SG151283A1 (en) * 2004-03-26 2009-04-30 Promics Pty Ltd Treatment of neurological conditions using complement c5a receptor modulators
CA2602375C (en) 2005-03-23 2018-07-24 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US7649951B2 (en) 2006-08-16 2010-01-19 Harris Corporation System and method for communicating data using symbol-based randomized orthogonal frequency division multiplexing (OFDM) with applied frequency domain spreading
CN101506237B (zh) 2006-08-22 2014-05-07 G2炎症私人有限公司 具有改进性能的抗-C5aR抗体
US8084024B2 (en) 2006-08-22 2011-12-27 G2 Inflammation Pty Ltd Method for producing antibodies
WO2008030564A2 (en) 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
AU2008314697B2 (en) 2007-10-22 2013-08-29 Merck Serono S.A. Single IFN-beta fused to a mutated lgG Fc fragment
EP2826791A3 (en) 2008-02-20 2015-07-29 Novo Nordisk A/S Humanized anti-C5aR antibodies
WO2010000864A1 (en) 2008-07-04 2010-01-07 Novo Nordisk A/S Method for producing monoclonal antibodies
EP2538973A2 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Stable antibody containing compositions
CA2800188A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative

Also Published As

Publication number Publication date
US20120315275A1 (en) 2012-12-13
US20130129721A1 (en) 2013-05-23
JP2014193164A (ja) 2014-10-09
EP2254911A4 (en) 2011-10-19
WO2009103113A1 (en) 2009-08-27
JP2011515073A (ja) 2011-05-19
EP2826791A3 (en) 2015-07-29
AU2009217224B2 (en) 2014-09-11
JP6034826B2 (ja) 2016-11-30
US8268972B2 (en) 2012-09-18
EP2254911A1 (en) 2010-12-01
KR20100117120A (ko) 2010-11-02
RU2010138612A (ru) 2012-03-27
EP2826791A2 (en) 2015-01-21
AU2009217224A1 (en) 2009-08-27
CA2714296A1 (en) 2009-08-27
US8361468B2 (en) 2013-01-29
IL207217A0 (en) 2010-12-30
CN104193824A (zh) 2014-12-10
CN101970494A (zh) 2011-02-09
ZA201005348B (en) 2011-10-26
IL207217A (en) 2015-03-31
ES2562627T3 (es) 2016-03-07
US8808701B2 (en) 2014-08-19
BRPI0907532A2 (pt) 2015-07-28
US20110190477A1 (en) 2011-08-04
CN101970494B (zh) 2015-01-21
EP2254911B1 (en) 2015-11-25

Similar Documents

Publication Publication Date Title
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
PH12019500438A1 (en) Anti-gcc antibody molecules and related compositions and methods
MX2010010387A (es) Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
MX355181B (es) Anticuerpos humanos contra el factor tisular.
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
MX357193B (es) Moleculas de union anti-alfa sinucleina.
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
NZ626610A (en) Antibodies that bind csf1r
SG184310A1 (en) Antibodies that bind human cd27 and uses thereof
EP4349868A3 (en) Humanized and chimeric monoclonal antibodies to cd47
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
MY150709A (en) Human cytomegalovirus neutralising antibodies and use thereof
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
NO20090069L (no) Malrettede forbindelser rettet mot binding til PDGFR-alfa og deres anvendelse
MX2010006767A (es) Anticuerpos de virus de hepatitis c.
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
UA99339C2 (ru) Антитело, которое специфично связывает человеческий tyrp1
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof
TN2012000151A1 (en) Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2
NZ757754A (en) Antibodies that bind csf1r
UA109423C2 (uk) Композиція та спосіб для діагностики і лікування пухлини

Legal Events

Date Code Title Description
FG Grant or registration